Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.60 |
| ▸ | CES1 | P23141 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetone SCHEMBL28575425 | 0.95 | CES2 (0.60) | CES2CES1PTPN1POLBKMT2A | |
| Methyl Alcohol SCHEMBL11566008 | 0.93 | CES2 (0.62) | CES2CES1PTPN1POLBKMT2A | |
| SCHEMBL24446 | 0.93 | — | — | |
| SCHEMBL3811314 | 0.93 | CES2 (0.68) | CES2CES1PTPN1POLBKMT2A | |
| SCHEMBL28143240 | 0.91 | CES2 (0.56) | CES2CES1PTPN1POLBKMT2A | |
| Acetamide SCHEMBL4667041 | 0.91 | PTGS1 (0.57) | CES2CES1PTPN1POLBKMT2A | |
| SCHEMBL6129939 | 0.91 | CES2 (0.60) | CES2CES1PTPN1POLBKMT2A | |
| Methylamine SCHEMBL27782227 | 0.91 | CES2 (0.60) | CES2CES1PTPN1POLBKMT2A | |
| SCHEMBL25196785 | 0.91 | — | — | |
| Ammonia Solution, Strong SCHEMBL6719610 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11975023-B2 | Methods for inhibiting anaerobic microorganisms | LPOXY THERAPEUTICS, INC (US) | 2024-05-07 | — | — | US | claimed |
| US-11944641-B2 | Treatment of inflammatory bowel diseases through administration of enteric aerobization therapy | LPOXY THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | claimed |
| US-11883428-B2 | Enteric aerobization therapy | LPOXY THERAPEUTICS, INC. (US) | 2024-01-30 | — | — | US | claimed |
| CN-106687099-A | Personal care compositions comprising malodor reduction compositions | 宝洁公司 | 2017-05-17 | — | — | CN | claimed |
| WO-2006002031-A1 | SUSTAINED RELEASE DOSAGE FORMS | ANDRX CORPORATION (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050276849-A1 | Sustained release dosage forms | ANDRX CORPORATION | 2005-12-15 | — | — | US | claimed |
| EP-4398876-A1 | ENTERIC AEROBIZATION THERAPY | Lpoxy Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-12036239-B2 | Treatment of inflammatory bowel diseases through administration of enteric aerobization therapy | LPOXY THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118284405-A | Intestinal aerobic therapy | 卢普奥克西治疗公司 | 2024-07-02 | — | — | CN | disclosed |
| US-11975023-B2 | Methods for inhibiting anaerobic microorganisms | LPOXY THERAPEUTICS, INC (US) | 2024-05-07 | — | — | US | disclosed |
| US-11944641-B2 | Treatment of inflammatory bowel diseases through administration of enteric aerobization therapy | LPOXY THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-11883428-B2 | Enteric aerobization therapy | LPOXY THERAPEUTICS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230277497-A1 | ENTERIC AEROBIZATION THERAPY | LPOXY THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-4200098-A | Osmotic system with distribution zone for dispensing beneficial agent | ALZA CORPORATION (US) | 1980-04-29 | — | — | US | disclosed |
| US-4160452-A | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina | ALZA CORPORATION (US) | 1979-07-10 | — | — | US | disclosed |
| US-4116241-A | FOR CONTROLLED ORAL ADMINISTRATION OF DRUG | ALZA CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4077407-A | POLYSACCHARIDES | ALZA CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
| US-4058122-A | Osmotic system with laminated wall formed of different materials | ALZA CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-4014334-A | Laminated osmotic system for dispensing beneficial agent | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-4008719-A | Osmotic system having laminar arrangement for programming delivery of active agent | ALZA CORPORATION (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11975023-B2 | Methods for inhibiting anaerobic microorganisms | SI, MB, ALPI | AGTR1 4187/4885CES2 4399/4885CES1 2062/4885 |
| US-12036239-B2 | Treatment of inflammatory bowel diseases through administration of enteric aerobization therapy | MB, NOD2, SI | AGTR1 3718/4885CES2 4632/4885CES1 3013/4885 |
| US-11883428-B2 | Enteric aerobization therapy | SI, MB, LPO | AGTR1 1536/4885CES2 3885/4885CES1 1665/4885 |
| US-11944641-B2 | Treatment of inflammatory bowel diseases through administration of enteric aerobization therapy | MB, NOD2, SI | AGTR1 3718/4885CES2 4632/4885CES1 3013/4885 |
| US-20230277497-A1 | ENTERIC AEROBIZATION THERAPY | SI, ALDOA, DERA | AGTR1 1773/4885CES2 3581/4885CES1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.